Immunotherapy specifically aimed at enhancing the number and effector function of these BRAFV600E-specific CD8+ T cells could offer great promise in the treatment of high-risk LCH-patients, given that these patients often bear the BRAFV600E mutation and fail first-line chemotherapy (44). Here, CD8A is linked to Langerhans cell histiocytosis.